Pharmacogenetics of antihypertensive treatment: Detailing disciplinary dissonance

Pharmacogenomics

Volumn 10, Issue 8, 2009, Pages 1295-1307

  Arnett, Donna K ^a   Claas, Steven A ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Antihypertensive; Blood pressure; Gene; Pharmacogenetics; Pharmacogenomics

Indexed keywords

ALPHA ADDUCIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN II; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL VOLTAGE DEPENDENT L TYPE ALPHA 1C SUBUNIT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FOSINOPRIL; FUNGAL PROTEIN; IRBESARTAN; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE PRECURSOR; PERINDOPRIL; PROTEIN KINASE WNK1; SODIUM CHANNEL; SODIUM CHANNEL NONVOLTAGE GATED 1 GAMMA SUBUNIT; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; UBIQUITIN PROTEIN LIGASE NEDD4; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; YEATS DOMAIN CONTAING PROTEIN 4;

ANTIHYPERTENSIVE THERAPY; DRUG EFFICACY; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEART INFARCTION; HUMAN; HYPERTENSION; PHARMACOGENETICS; PHENOTYPE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STROKE;

ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; METABOLIC DETOXICATION, DRUG; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 70649094353     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.61     Document Type: Review

References (72)

1. Rosamond W, Flegal K, Furie K et al.: Heart Disease and Stroke Statistics 2008 Update. A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117(4), E25-E146 (2008).
2. Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. II. Results of long-term therapy. Veterans Administration Cooperative Study Group on Antihypertensive Agents. JAMA 248, 2004-2011 (1982).
3. Materson BJ: Variability in response to antihypertensive drugs. Am. J. Med. 120, S10-S20 (2007).
4. Turner ST, Bailey KR, Fridley BL et al.: Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic. Hypertension 52, 359-365 (2008). ■ Illustrates the potential that the genome-wide association study methodology has or identifying novel genes that may play a role in the response to antihypertensive drug treatment. Such studies may prove not only valuable in the move toward clinical pharmacogenetics, but they may also advance our biological understanding of hypertension and its treatment.
5. Haas M, Yilmaz N, Schmidt A et al.: Angiotensin-converting enzyme gene polymorphism determines the antiproteinuric and systemic hemodynamic effect of enalapril in patients with proteinuric renal disease. Austrian Study Group of the Effects of Enalapril Treatment in Proteinuric Renal Disease. Kidney Blood Press. Res. 21, 66-69 (1998).
6. Turner ST, Schwartz GL, Chapman AB, Boerwinkle E: C825T polymorphism of the G protein β(3)-subunit and antihypertensive response to a thiazide diuretic. Hypertension 37, 739-743 (2001).
7. Liu J, Liu ZQ, Yu BN et al.: β1-adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension. Clin. Pharmacol. Ther. 80, 23-32 (2006). (Pubitemid 43946840)
8. Siest G, Jeannesson E, Visvikis-Siest S: Enzymes and pharmacogenetics of cardiovascular drugs. Clin. Chim. Acta 381, 26-31 (2007).
9. Flaa A, Kjeldsen SE: Are all the hypertensives made equal? Herz. 31, 323-330 (2006). (Pubitemid 44046495)
10. Israili ZH, Hernandez-Hernandez R, Valasco M: The future of antihypertensive treatment. Am. J. Ther. 14, 121-134 (2007).
11. Filigheddu F, Troffa C, Glorioso N: Pharmacogenomics of essential hypertension: are we going the right way? Cardiovasc. Hematol. Agents Med. Chem. 4, 7-15 (2006). (Pubitemid 43796696)
12. Mellen PB, Herrington DM: Pharmacogenomics of blood pressure response to antihypertensive treatment. J. Hypertens. 23, 1311-1325 (2005).
13. Saavedra JM: Studies on genes and hypertension: a daunting task. J. Hypertens. 23, 929-932 (2005).
14. Manunta P, Bianchi G: Pharmacogenomics and pharmacogenetics of hypertension: update and perspectives - the adducin paradigm. J. Am. Soc. Nephrol. 17, S30-S35 (2006).
15. Kurland L, Lind L, Melhus H: Using genotyping to predict responses to antihypertensive treatment. Trends Pharmacol. Sci. 26, 443-447 (2005). (Pubitemid 41207875)
16. Arnett DK, Claas SA, Glasser SP: Pharmacogenetics of antihypertensive treatment. Vascul. Pharmacol. 44, 107-118 (2006).
17. Johnson JA, Turner ST: Hypertension pharmacogenomics: current status and future directions. Curr. Opin. Mol. Ther. 7, 218-225 (2005).
18. Schwartz GL, Turner ST: Pharmacogenetics of antihypertensive drug responses. Am. J. Pharmacogenomics 4, 151-160 (2004).
19. Kurland L, Hallberg P, Melhus H et al.: The relationship between the plasma concentration of irbesartan and the antihypertensive response is disclosed by an angiotensin II type 1 receptor polymorphism: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA) Trial. Am. J. Hypertens. 21, 836-839 (2008). (Pubitemid 351913624)
20. Lynch AI, Boerwinkle E, Davis BR et al.: Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension. JAMA 299, 296-307 (2008). ■■ This research using data from the largest pharmacogenetic study to date showed a pharmacogenetic effect of an natriuretic peptide precursor (NPPA) variant on multiple outcomes. The consistency of the association with multiple clinical outcomes and blood pressure change lends credibility to the findings. (Pubitemid 351159366)
21. Langaee TY, Gong Y, Yarandi HN et al.: Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil. Clin. Pharmacol. Ther. 81, 386-391 (2007). (Pubitemid 46364490)
22. Pacanowski MA, Gong Y, Cooper-Dehoff RM et al.: β-adrenergic receptor gene polymorphisms and β-blocker treatment outcomes in hypertension. Clin. Pharmacol. Ther. 84, 715-721 (2008).
23. Lemaitre RN, Heckbert SR, Sotoodehnia N et al.: β1- and β2-adrenergic receptor gene variation, β-blocker use and risk of myocardial infarction and stroke. Am. J. Hypertens. 21, 290-296 (2008). (Pubitemid 351323282)
24. Lanfear DE, Jones PG, Marsh S, Cresci S, McLeod HL, Spertus JA: β2-adrenergic receptor genotype and survival among patients receiving β-blocker therapy after an acute coronary syndrome. JAMA 294, 1526-1533 (2005). (Pubitemid 41362690)
25. Maitland-van der Zee AH, Turner ST, Schwartz GL, Chapman AB, Klungel OH, Boerwinkle E: A multilocus approach to the antihypertensive pharmacogenetics of hydrochlorothiazide. Pharmacogenet. Genomics 15, 287-293 (2005).
26. Beitelshees AL, Gong Y, Wang D et al.: KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the International Verapamil SR/Trandolapril Study (INVEST). Pharmacogenet. Genomics 17, 719-729 (2007). (Pubitemid 47263067)
27. Kelley-Hedgepeth A, Peter I, Kip K et al.: The protective effect of KCNMB1 E65K against hypertension is restricted to blood pressure treatment with β-blockade. J. Hum. Hypertens. 22, 512-515 (2008). (Pubitemid 351877740)
28. Bremer T, Man A, Kask K, Diamond C: CACNA1C polymorphisms are associated with the efficacy of calcium channel blockers in the treatment of hypertension. Pharmacogenomics 7, 271-279 (2006).
29. Milionis HJ, Kostapanos MS, Vakalis K et al.: Impact of renin-angiotensin-aldosterone system genes on the treatment response of patients with hypertension and metabolic syndrome. J. Renin Angiotensin Aldosterone Syst. 8, 181-189 (2007). (Pubitemid 351166265)
30. Chobanian AV, Bakris GL, Black HR et al.: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42, 1206-1252 (2003).
31. Cutler JA, Davis BR: Thiazide-type diuretics and β-adrenergic blockers as first-line drug treatments for hypertension. Circulation 117, 2691-2704; discussion 2705 (2008).
32. Messerli FH, Bangalore S, Julius S: Risk/benefit assessment of β-blockers and diuretics precludes their use for first-line therapy in hypertension. Circulation 117, 2706-2715; discussion 2715 (2008).
33. Turner ST, Chapman AB, Schwartz GL, Boerwinkle E: Effects of endothelial nitric oxide synthase, α-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide. Am. J. Hypertens. 16, 834-839 (2003).
34. Rodwell GE, Sonu R, Zahn JM et al.: A transcriptional profile of aging in the human kidney. PLoS Biol. 2, E427 (2004). (Pubitemid 40280523)
35. Manunta P, Lavery G, Lanzani C et al.: Physiological interaction between α-adducin and WNK1-NEDD4L pathways on sodium-related blood pressure regulation. Hypertension 52, 366-372 (2008).
36. Bangalore S, Parkar S, Grossman E, Messerli FH: A meta-analysis of 94,492 patients with hypertension treated with β blockers to determine the risk of new-onset diabetes mellitus. Am. J. Cardiol. 100, 1254-1262 (2007). (Pubitemid 47498283)
37. Schelleman H, Klungel OH, Witteman JC et al.: Angiotensinogen M235T polymorphism and the risk of myocardial infarction and stroke among hypertensive patients on ACE-inhibitors or β-blockers. Eur. J. Hum. Genet. 15, 478-484 (2007). (Pubitemid 46487703)
38. Schelleman H, Klungel OH, Witteman JC et al.: Interaction between polymorphisms in the renin-angiotensin-system and angiotensin-converting enzyme inhibitor or β-blocker use and the risk of myocardial infarction and stroke. Pharmacogenomics J. 8, 400-407 (2008).
39. Jauch KW, Hartl W, Guenther B, Wicklmayr M, Rett K, Dietze G: Captopril enhances insulin responsiveness of forearm muscle tissue in non-insulin- dependent diabetes mellitus. Eur. J. Clin. Invest. 17, 448-454 (1987). (Pubitemid 18063913)
40. Gluszek J, Jankowska K: Is there relationship between the A1166C polymorphism of the angiotensin II receptor AT1 and plasma renin activity, insulin resistance and reduction of blood pressure after angiotensin-converting enzyme inhibitor therapy? Pol. Arch. Med. Wewn. 118, 194-200 (2008). (Pubitemid 351613059)
41. Hingorani AD, Jia H, Stevens PA, Hopper R, Dickerson JE, Brown MJ: Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. J. Hypertens. 13, 1602-1609 (1995). (Pubitemid 26015783)
42. Dudley C, Keavney B, Casadei B, Conway J, Bird R, Ratcliffe P: Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: investigation of renin-angiotensin system genes. J. Hypertens. 14, 259-262 (1996). (Pubitemid 26121870)
43. Bis JC, Smith NL, Psaty BM et al.: Angiotensinogen Met235Thr polymorphism, angiotensin-converting enzyme inhibitor therapy, and the risk of nonfatal stroke or myocardial infarction in hypertensive patients. Am. J. Hypertens. 16, 1011-1017 (2003).
44. Arnett DK, Davis BR, Ford CE et al.: Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study. Circulation 111, 3374-3383 (2005).
45. Filigheddu F, Argiolas G, Bulla E et al.: Clinical variables, not RAAS polymorphisms, predict blood pressure response to ACE inhibitors in Sardinians. Pharmacogenomics 9, 1419-1427 (2008).
46. Johnson AD, Gong Y, Wang D et al.: Promoter polymorphisms in ACE (angiotensin I-converting enzyme) associated with clinical outcomes in hypertension. Clin. Pharmacol. Ther. 85, 36-44 (2009).
47. Coy V: Genetics of essential hypertension. J. Am. Acad. Nurse Pract. 17, 219-224 (2005).
48. Shin J, Johnson JA: Pharmacogenetics of β-blockers. Pharmacotherapy 27, 874-887 (2007).
49. Filigheddu F, Reid JE, Troffa C et al.: Genetic polymorphisms of the β-adrenergic system: association with essential hypertension and response to β-blockade. Pharmacogenomics J. 4, 154-160 (2004). (Pubitemid 38786553)
50. Farahani P, Dolovich L, Levine M: Exploring design-related bias in clinical studies on receptor genetic polymorphism of hypertension. J. Clin. Epidemiol. 60, 1-7 (2007).
51. Frazier L, Turner ST, Schwartz GL, Chapman AB, Boerwinkle E: Multilocus effects of the renin-angiotensin-aldosterone system genes on blood pressure response to a thiazide diuretic. Pharmacogenomics J. 4, 17-23 (2004). (Pubitemid 38256600)
52. Ziegler A, Konig IR, Thompson JR: Biostatistical aspects of genome-wide association studies. Biom. J. 50, 8-28 (2008).
53. Brain N Jr, Dominiczak AF: Pharmacogenomics in hypertension: present practicalities and future potential. J. Hypertens. 23, 1327-1329 (2005).
54. Taylor MR: Pharmacogenetics of the human β-adrenergic receptors. Pharmacogenomics J. 7, 29-37 (2007).
55. Fornage M: Unraveling hypertension: epigenomics comes of age. Pharmacogenomics 8, 125-128 (2007).
56. Magnusson Y, Levin MC, Eggertsen R et al.: Ser49Gly of β1-adrenergic receptor is associated with effective β-blocker dose in dilated cardiomyopathy. Clin. Pharmacol. Ther. 78, 221-231 (2005). (Pubitemid 41254107)
57. Julius S, Nesbitt SD, Egan BM et al.: Feasibility of treating prehypertension with an angiotensin-receptor blocker. N. Engl. J. Med. 354, 1685-1697 (2006).
58. Lumley T, Rice KM, Psaty BM: Carryover effects after cessation of drug treatment: trophies or dreams? Am. J. Hypertens. 21, 14-16 (2008).
59. Arnett DK, Tang W, Province MA et al.: Interarm differences in seated systolic and diastolic blood pressure: the Hypertension Genetic Epidemiology Network study. J. Hypertens. 23, 1141-1147 (2005). (Pubitemid 40862717)
60. Stergiou GS, Baibas NM, Gantzarou AP et al.: Reproducibility of home, ambulatory, and clinic blood pressure: implications for the design of trials for the assessment of antihypertensive drug efficacy. Am. J. Hypertens. 15, 101-104 (2002).
61. Charchar FJ, Zimmerli LU, Tomaszewski M: The pressure of finding human hypertension genes: new tools, old dilemmas. J. Hum. Hypertens. 22, 821-828 (2008).
62. Glorioso N, Manunta P, Filigheddu F et al.: The role of α-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study. Hypertension 34, 649-654 (1999). (Pubitemid 29496448)
63. Sciarrone MT, Stella P, Barlassina C et al.: ACE and α-adducin polymorphism as markers of individual response to diuretic therapy. Hypertension 41, 398-403 (2003). (Pubitemid 36314607)
64. Kaye DM, Smirk B, Williams C, Jennings G, Esler M, Holst D: β-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure. Pharmacogenetics 13, 379-382 (2003). (Pubitemid 36900732)
65. Johnson JA, Zineh I, Puckett BJ, McGorray SP, Yarandi HN, Pauly DF: β 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin. Pharmacol. Ther. 74, 44-52 (2003). (Pubitemid 36776175)
66. Liu J, Liu ZQ, Tan ZR et al.: Gly389Arg polymorphism of β1-adrenergic receptor is associated with the cardiovascular response to metoprolol. Clin. Pharmacol. Ther. 74, 372-379 (2003). (Pubitemid 37222858)
67. Sofowora GG, Dishy V, Muszkat M et al.: A common β1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to β-blockade. Clin. Pharmacol. Ther. 73, 366-371 (2003). (Pubitemid 36403596)
68. Hindorff LA, Heckbert SR, Psaty BM et al.: β(2)-adrenergic receptor polymorphisms and determinants of cardiovascular risk: the Cardiovascular Health Study. Am. J. Hypertens. 18, 392-397 (2005).
69. Stavroulakis GA, Makris TK, Krespi PG et al.: Predicting response to chronic antihypertensive treatment with fosinopril: the role of angiotensin-converting enzyme gene polymorphism. Cardiovasc. Drugs Ther. 14, 427-432 (2000).
70. Miller JA, Thai K, Scholey JW: Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II. Kidney Int. 56, 2173-2180 (1999). (Pubitemid 30004746)
71. Karlsson J, Lind L, Hallberg P et al.: β1-adrenergic receptor gene polymorphisms and response to β1-adrenergic receptor blockade in patients with essential hypertension. Clin. Cardiol. 27, 347-350 (2004). (Pubitemid 38703089)
72. Dishy V, Sofowora GG, Xie HG et al.: The effect of common polymorphisms of the β2-adrenergic receptor on agonist-mediated vascular desensitization. N. Engl. J. Med. 345, 1030-1035 (2001). (Pubitemid 34940795)